DBV Technologies S.A. (DBVT): Free Cash Flow
-$121.71M
Year ended 2025-12-31
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$121.71M | n/m | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | -$106.81M | n/m | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | -$80.33M | n/m | 2025-04-11, From 2023-01-01 |
| 2022-12-31 | -$56.42M | n/m | 2024-03-07, From 2022-01-01 |
| 2021-12-31 | -$109.15M | n/m | 2023-03-02, From 2021-01-01 |
| 2020-12-31 | -$168.40M | n/c | 2022-03-09, From 2020-01-01 |
| 2019-12-31 | -$153.91M | n/a | 2021-03-17, From 2019-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| DBV Technologies S.A. (DBVT) | 2025-12-31 | -$121.71M | n/m |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | -$741.0K | n/a |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | -$112.04M | n/m |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | -$167.09M | n/m |
| Ocugen, Inc. (OCGN) | 2025-12-31 | -$57.15M | n/m |
| CG Oncology, Inc. (CGON) | 2025-12-31 | -$132.48M | n/m |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | -$345.93M | n/m |
| Surrozen, Inc. (SRZN) | 2025-12-31 | -$30.37M | n/m |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | -$93.83M | n/m |
Compare DBVT, ZEOX, FATE, PRME side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗